Difference between revisions of "Paclitaxel (Taxol)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Uterine" to "[[Category:Endometrial") |
m |
||
Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
+ | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
*[[Adenocarcinoma of unknown primary]] | *[[Adenocarcinoma of unknown primary]] | ||
*[[Cutaneous basal cell carcinoma]] | *[[Cutaneous basal cell carcinoma]] | ||
Line 27: | Line 28: | ||
*[[Uterine cancer]] | *[[Uterine cancer]] | ||
*[[Vascular sarcoma]] | *[[Vascular sarcoma]] | ||
− | + | *[[Vulvar cancer]] | |
+ | </div> | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Paclitaxel (Taxol) package insert]<ref name="insert"></ref> | *[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf Paclitaxel (Taxol) package insert]<ref name="insert"></ref> | ||
Line 129: | Line 131: | ||
[[Category:Cervical cancer medications]] | [[Category:Cervical cancer medications]] | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
+ | [[Category:Endometrial cancer medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
Line 141: | Line 144: | ||
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
− | |||
[[Category:Vascular sarcoma medications]] | [[Category:Vascular sarcoma medications]] | ||
+ | [[Category:Vulvar cancer medications]] | ||
[[Category:FDA approved in 1992]] | [[Category:FDA approved in 1992]] | ||
[[Category:PMDA approved drugs]] | [[Category:PMDA approved drugs]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] |
Revision as of 03:40, 20 November 2018
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization. Paclitaxel interferes with the normal dynamic reorganization of microtubules that is necessary for regular interphase/mitosis processes. It also leads to creation of abnormal bundles of microtubules. Paclitaxel is highly lipophilic/insoluble in water and needs to be dissolved in Cremophor EL (polyoxyethylated castor oil), which may cause hypersensitivity infusion reactions.[1][2]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adenocarcinoma of unknown primary
- Cutaneous basal cell carcinoma
- Bladder cancer
- Breast cancer
- Cervical cancer
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Gastric cancer
- Head and neck cancer
- Melanoma
- Non-small cell lung cancer
- Ovarian cancer
- Penile cancer
- Prostate cancer
- SCC of unknown primary
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Uterine cancer
- Vascular sarcoma
- Vulvar cancer
Patient drug information
- Paclitaxel (Taxol) package insert[1]
- Paclitaxel (Taxol) patient drug information (Chemocare)[3]
- Paclitaxel (Taxol) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 12/29/1992: Initial FDA approval (label is not available)
- 4/9/1998 (earliest label available on Drugs @ FDA): Indicated for:
- First-line and subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, Taxol is indicated in combination with cisplatin.
- The treatment of breast cancer after failure of combination therapy for metastatic disease or relapsed within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- The second-line treatment of AIDS-related Kaposi's sarcoma.
- 6/30/1998: New indication added: in combination with cisplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
- 10/25/1999: New indication for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy.
Also known as
- Brand names:
Synonyms | |||||||
---|---|---|---|---|---|---|---|
Abitaxel | Altaxel | Anzatax | Anzatec | Asotax | Betaxel | Bristaxol | Britaxol |
Clitaxel | Cytax | Daburex | Dalys | Drifen | Ebetaxel | Formoxol | Genaxol |
Genetaxyl | Gros | Ifaxol | Intaxel | Magytax | Medixel | Mitotax | Neotacs |
Neotaxan | Neotaxl | Ofoxel | Oncotaxel | Onxol | Paclitax | Paclitaxel | Paclitaxin |
Pacliteva | Pacxel | Padexol | Paklitaxfil | Panataxel | Parexel | Paxene | Paxenor |
Paxus | Petaxel | Phyxol | Poltaxel | Praxel | Ribotax | Sindaxel | Taclipaxol |
Tarvexol | Taxocris | Taxodiol | Taxol | Taxomedac | Taycovit | Unitaxel | Yewtaxan |
References
- Drugs
- Intracavitary medications
- Intravenous medications
- Irritant chemotherapy
- Vesicant chemotherapy
- Taxanes
- Microtubule inhibitors
- Adenocarcinoma of unknown primary medications
- Cutaneous basal cell carcinoma medications
- Bladder cancer medications
- Breast cancer medications
- Cervical cancer medications
- Diffuse large B-cell lymphoma medications
- Endometrial cancer medications
- Esophageal cancer medications
- Gastric cancer medications
- Head and neck cancer medications
- Melanoma medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Penile cancer medications
- Prostate cancer medications
- SCC of unknown primary medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Vascular sarcoma medications
- Vulvar cancer medications
- FDA approved in 1992
- PMDA approved drugs
- WHO Essential Cancer Medicine